Anixa Biosciences (ANIX) investor relations material

Executive summary

• Focused on developing cancer vaccines and CAR-T therapies, with ongoing clinical trials in ovarian and breast cancer and new vaccine discovery programs targeting high-incidence cancers.

• No revenue generated from therapeutics or vaccine programs; legacy patent licensing activities are not expected to be significant going forward.

• Sufficient cash, cash equivalents, and short-term investments to fund operations for at least the next twelve months.

Financial highlights

• Net loss for the quarter ended April 30, 2026 was $2.5 million, compared to $2.8 million for the same quarter last year.

• Net loss for the six months ended April 30, 2026 was $5.1 million, down from $6.0 million year-over-year.

• Operating expenses for the quarter were $2.6 million, down from $3.0 million year-over-year.

• Cash, cash equivalents, and short-term investments totaled $13.7 million as of April 30, 2026, down from $15.2 million at October 31, 2025.

• Raised $2.87 million through an at-the-market equity offering during the six months ended April 30, 2026.

Outlook and guidance

• No expectation of near-term revenue from therapeutics or vaccine programs; profitability depends on future licensing deals, which may take several years and require positive clinical trial results.

• Development of therapeutics and vaccines will remain the primary focus in upcoming quarters.

• Sufficient liquidity to operate for significantly longer than 12 months from the report date.